Diagnostic Substances: Palatin Technologies (NYSEMKT:PTN), AMAG Pharmaceuticals (NASDAQ:AMAG), Trinity Biotech plc (NASDAQ:TRIB), Chembio Diagnostics (NASDAQ:CEMI)

Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).Palatin Technologies, Inc. (NYSEMKT:PTN) stock opened at $1.23 in last trading session, and closed at $1.15, trading in the range of $1.13 – $1.28.

AMAG Pharmaceuticals (NASDAQ:AMAG) had its target price increased by Jefferies Group from $19.00 to $21.00. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares closed at $21.76 on last trade day, by gaining 1.92%. Stock 52 week range is $15.90 – $28.42. Company’s market capitalization is $474.37 million.

Trinity Biotech plc (ADR) (NASDAQ:TRIB) average recommendation is buy with average Target Price of $33. Trinity Biotech plc (ADR) (NASDAQ:TRIB) stock advanced 0.53% and finished the last session at $26.69. The EPS of the stock remained 0.41. Company’s market capitalization is $576.23 million.

Chembio Diagnostics Inc (NASDAQ:CEMI) average recommendation is buy with average Target Price of $7.00. Chembio Diagnostics Inc (NASDAQ:CEMI) stock opened at $3.27 in last trading session and closed at $3.50. The 52 week range of the stock is $2.98 – 5.70 and the day range was $2.98 – $3.55.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *